(Q46862632)

25 December 2017

title

Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials (English)

1 reference

25 December 2017

1 reference

5

John Collins

1 reference

25 December 2017

author name string

Lorenzo Gianni

1

1 reference

25 December 2017

Ilaria Panzini

2

1 reference

25 December 2017

Sigui Li

3

1 reference

25 December 2017

Richard D Gelber

4

1 reference

25 December 2017

Stig B Holmberg

6

1 reference

25 December 2017

Diana Crivellari

7

1 reference

25 December 2017

Monica Castiglione-Gertsch

8

1 reference

25 December 2017

Aron Goldhirsch

9

1 reference

25 December 2017

Alan S Coates

10

1 reference

25 December 2017

Alberto Ravaioli

11

1 reference

25 December 2017

International Breast Cancer Study Group (IBCSG)

12

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

25 December 2017

published in

Cancer

1 reference

25 December 2017

volume

106

1 reference

25 December 2017

issue

3

1 reference

25 December 2017

page(s)

505-513

1 reference

25 December 2017

cites work

Tamoxifen maculopathy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

Retinal changes associated with tamoxifen treatment for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

Ocular toxicity in low-dose tamoxifen: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

Incidence of age-related cataract: the Beaver Dam Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

First do no harm: extending the debate on the provision of preventive tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Side effects of adjuvant treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Tamoxifen-associated eye disease. A review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Ocular toxicity and cancer chemotherapy. A review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Tamoxifen in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Ocular side‐effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow‐up study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Inhibition of 5-fluorouracil-induced ocular irritation by ocular ice packs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Tamoxifen retinopathy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Bilateral optic neuritis evolved during tamoxifen treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Tamoxifen retinopathy at low dosage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Reversible ocular toxicity related to tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Tamoxifen retinopathy: a rare but serious complication

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Retinopathy associated with low-dose tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Tamoxifen retinopathy in a male patient.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Should we discontinue tamoxifen in a patient with vision-threatening ocular toxicity related to low-dose tamoxifen therapy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Retinal changes associated with tamoxifen treatment for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Retinopathy caused by treatment with tamoxifen in low dosage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Screening for ocular toxicity in asymptomatic patients treated with tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Tamoxifen retinopathy: does it really exist?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Long-term tamoxifen citrate use and potential ocular toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

A method for estimating the probability of adverse drug reactions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Ocular toxicity associated with systemic drug therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Eye problems in breast cancer patients treated with tamoxifen.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Tamoxifen and cataracts: a null association

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Intraocular penetration of tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Effects of tamoxifen, toremifene and chloroquine on the lysosomal enzymes in cultured retinal pigment epithelial cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Protective effects of estrogen in a rat model of age-related cataracts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Volume regulation in the bovine lens and cataract. The involvement of chloride channels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Tamoxifen blocks chloride channels. A possible mechanism for cataract formation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Estrogen receptor regulation of the Na+/H+ exchange regulatory factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21651

7 January 2021

Identifiers

DOI

10.1002/CNCR.21651

1 reference

25 December 2017

1 reference

25 December 2017